Clinical characteristics and mortality outcomes of acute kidney injury following COVID-19 infection in patients with chronic kidney disease at different stages Authors: Xianhong Ding, Tong Sun, Mengyuan Chen, Tianbin Tang, Guangjun Zhu, Ying Zhang, Shenyi Ye, Yang Lu, Bo Shen Published: 2025 ABSTRACT AbstractObjectiveTo analyze the incidence, clinical characteristics, and mortality risk of acute kidney injury (AKI) in patients with preexisting chronic kidney disease (CKD) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and further provide evidence-based guidance for reducing AKI-related mortality and promoting the recovery of renal function in this specific patient cohort.MethodsA total of 1,820 hospitalized COVID-19 patients admitted between December 7, 2022, and January 31, 2023, Patients were stratified into four groups based on two key criteria: their preexisting chronic kidney disease (CKD) history and whether they developed acute kidney injury (AKI) during the hospitalization period: CKD-AKI group (CKD with AKI), CKD-Non AKI group (CKD without AKI), Non CKD-AKI group (AKI without CKD), and Non CKD-Non AKI group (no CKD and no AKI). Baseline characteristics, laboratory parameters, and outcomes were compared across the four groups. Key analyses focused on clinical features of AKI in CKD-AKI vs. Non CKD-AKI groups, AKI incidence and mortality rates across CKD stages, and risk factors for AKI development and causes of death.ResultsAmong 1,820 enrolled patients, 205 (11.3%) developed AKI. The AKI incidence was higher in the CKD group than in the Non CKD group (26.0% vs. 9.7%). The duration of AKI was significantly longer in the CKD-AKI group than in the Non CKD-AKI group (P < 0.05). Among CKD-AKI patients, both the time from COVID-19 onset to AKI development and the time from AKI onset to peak serum creatinine level were significantly longer in non-survivors than in survivors (both P < 0.05). In patients with CKD, the incidence of AKI increased progressively with advancing CKD stages, ranging from 12.5% in stage 3b to 55.8% in stage 5, with AKI stage 2 being the most prevalent (47.8%). Fatal cases were predominantly concentrated in CKD stages 3b to 5, accounting for 74.2% (23/31) of all CKD-related deaths. Analysis of organ failure in fatal cases demonstrated that the incidence of renal failure was higher in the CKD-AKI group than in the Non CKD-AKI group (50% vs. 15%).ConclusionPatients with end-stage chronic kidney disease and COVID-19 are at a substantially increased risk of AKI, particularly in critical illness. This complication is independently associated with elevated mortality, underscoring the imperative for early, serial renal function monitoring and prompt intervention to mitigate adverse outcomes.Clinical trial numberNot applicable.Graphical Abstract Keywords: COVID-19, Chronic kidney disease, Acute kidney injury, Mortality Introduction COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic posing significant challenges to public health [1]. COVID-19 patients exhibit diverse clinical presentations, ranging from respiratory symptoms to systemic complications such as fever, loss of smell, diarrhea, and multi-organ dysfunction [2]. Among these complications, the occurrence of acute kidney injury (AKI) is particularly noteworthy, with a markedly elevated incidence observed in critically ill patients [3]. The kidneys represent one of the primary targets attacked by SARS-CoV-2. This occurs because the virus binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cell surfaces via its spike protein. ACE2 exhibits high expression levels in the kidneys, distributed within the renal tubules and tubular epithelial cells. This binding facilitates viral replication within renal cells, ultimately leading to kidney damage [4, 5]. However, despite numerous studies examining the incidence and risk factors of AKI induced by SARS-CoV-2 infection [6–8], systematic analyses of the association between acute kidney injury (AKI) and mortality in patients with chronic kidney disease (CKD) after COVID-19 remain limited. This study therefore aims to characterize in depth the clinical features and outcomes of AKI in 177 CKD patients among a total of 1,820 patients following SARS-CoV-2 infection, providing reference information to guide clinical management, with the goal of reducing mortality and improving recovery. Materials and methods Research design This study primarily collected data on COVID-19 patients hospitalized at Enze Medical Center (Group) between December 7, 2022, and January 31, 2023. Inclusion criteria were based on laboratory-confirmed SARS-CoV-2 infection, with positive SARS-CoV-2 results detected via reverse transcription polymerase chain reaction (RT-PCR). Exclusion criteria were: (1) presence of any malignant tumor; (2) under 18 years age; (3) end-stage renal disease requiring hemodialysis or a history of kidney transplantation; (4) fewer than two recent serum creatinine measurements during the current hospitalization episode; (5) admission for causes unrelated to SARS-CoV-2 infection. Ultimately, 1,820 patients were included in this study. Participants were divided into four groups based on the presence of chronic kidney disease history and the occurrence of acute kidney injury during hospitalization: CKD-AKI group (46 cases), CKD-Non AKI group (131 cases), Non CKD-AKI group (159 cases), and Non CKD-Non AKI group (1,484 cases) (Fig. 1). Study design and process Abbreviations: COVID-19, coronavirus disease 2019; CKD, chronic kidney disease; Non CKD, no chronic kidney disease; AKI, acute kidney injury; Non AKI, no acute kidney injury Data collection and metric analysis Clinical data of 1,820 patients were extracted from electronic medical records, including demographic information (gender, age), comorbidities, medical history, onset time of COVID-19-related symptoms, length of hospital stay, discharge date, and treatment outcomes; for patients who developed AKI, the time of AKI onset, duration, and peak serum creatinine level were meticulously documented, while for non-survivors following AKI development, the types and sequence of organ failures preceding death were comprehensively recorded; baseline laboratory data upon admission were collected, including: Complete blood count (WBC, Lymphocyte), Liver function (ALT, AST, GGT, ALP, TB, DB, TP, ALB), Renal function (BUN, CREA, eGFR), Electrolytes (K, Na, Cl), C-reactive protein and coagulation parameters (PT, APTT, D-Dimer) C-reactive protein, and coagulation parameters (PT, APTT, D-dimer). Creatinine data were collected separately at multiple time points to assess the occurrence of acute kidney injury. Complete blood counts were performed using fully automated hematology analyzer (model XN9000;Sysmex, Japan); liver function parameters, renal function parameters, and electrolytes were measured with a fully automated biochemical analyzer (model AU5821; Beckman Coulter, Inc., Brea, CA, USA); coagulation function was assessed via an automated coagulation analyzer (model R Max; Stago, Asnières-sur-Seine, France); all testing procedures underwent daily dual-level quality control. All items participated in the National Health Commission’s interlaboratory quality assessment program, achieving excellent results. Definition Acute kidney injury (AKI) is defined according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria as one of the following: an increase in serum creatinine (SCr) of ≥ 0.3 mg/dL within 48 h; an increase of ≥ 50% from baseline within 7 days; Urine volume ≤ 0.5 ml/kg/h for 6 h [9]. AKI staging is categorized based on the degree of SCr change: Stage 1 (1.5–1.9 times baseline or ≥ 0.3 mg/dL), Stage 2 (2.0–2.9 times baseline), and Stage 3 (≥ 3 times baseline or requiring renal replacement therapy). The baseline SCr value should preferably be the lowest value recorded within 7 days prior to hospitalization. If unavailable, the median value from 7 to 365 days before admission is the secondary choice. The lowest serum creatinine value during hospitalization is the final alternative [10]. CKD is defined as persistent renal structural or functional abnormalities lasting >3 months (based on clinical diagnosis or eGFR) and is categorized into stages G1–G5 according to the Chinese Guidelines for Early Evaluation and Management of Chronic Kidney Disease [11]: G1: ≥90 mL/min/1.73m²;G2: 60-89mL/min/1.73m²;G3a: 45–59 mL/min/1.73 m²; G3b: 30–44 mL/min/1.73 m²; G4: 15–29 mL/min/1.73 m²; G5: <15 mL/min/1.73 m²). Time-related indicators following SARS-CoV-2 infection include: onset date (defined as the first day of COVID-19 related symptoms such as headache, fever, and cough), admission date (the date of hospital admission documented in medical records), and discharge date (the date of hospital discharge or death recorded in medical records); additional time-related indicators specific to AKI include: time of AKI onset (the first time the AKI diagnostic criteria were met), duration of AKI (the period from AKI onset to serum creatinine level declining to below 1.5 times the baseline value), and time to peak serum creatinine (the interval from COVID-19 symptom onset to the highest recorded serum creatinine value). Statistical methods Statistical analysis was performed using SPSS (version 26.0), GraphPad Prism (version 10.0), and R software (version 3.5.1). Categorical data were recorded as absolute values with percentages. Non-normally distributed continuous variables were expressed as medians or quartiles (interquartile ranges). Continuous variables between groups were compared using the Mann-Whitney U test, while the chi-square test was applied for categorical variables. A multivariate logistic regression model was used to identify factors associated with AKI incidence in CKD and Non CKD patients, as well as factors related to mortality in AKI patients, with a focus on independent risk factors.Variables with P < 0.05 were considered statistically significant. Result Clinical characteristics of 1,820 patients and AKI incidence comparison between CKD and Non CKD groups This study enrolled 1,820 hospitalized COVID-19 patients at Enze Medical Center (Group) between December 7, 2022, and January 31, 2023. The mean age of the cohort was 73.54 years, with 1,056 males (58.0%) and 764 females (42.0%), and the median length of hospital stay was 10 days. Comorbidities included diabetes mellitus in 477 patients (26.2%) and hypertension in 900 patients (49.5%). Following systematic treatment, 1,630 patients (89.5%) achieved clinical improvement and were discharged, while 190 patients died, resulting in an overall case fatality rate of 10.5%. Among 1,820 patients, 177 had baseline CKD while 1,643 did not (Non CKD). After admission, 205 patients developed AKI, accounting for 11.26%. The AKI incidence rate was 26.0% (46/177) in the CKD group and 9.7% (159/1643) in the Non CKD group. The findings indicate that patients with baseline CKD have a higher risk of developing AKI following SARS-CoV-2 infection compared to Non CKD patients. There were no significant differences between the CKD-AKI group and the CKD-Non AKI group in terms of age, gender, length of hospitalization, or underlying conditions (diabetes, hypertension). However, marked differences emerged in invasive mechanical ventilation and treatment outcomes: within the CKD-AKI group, 9 patients (19.6%) required invasive mechanical ventilation, and 16 patients (34.8%) died; while in the CKD-Non AKI group, 6 patients (4.6%) required invasive mechanical ventilation and 15 patients (11.5%) died. Additionally, laboratory data showed significant differences between the two groups for lymphocyte count, Na, ALB, BUN, CREA, eGFR, PT, APTT, and D-dimer (P < 0.05) (Table 1). Table 1Clinical baseline characteristicsTotal(n = 1820)CKD(n = 177)P-value1Non CKD(n = 1643)P-value2P-value3AKI (n = 46)Non-AKI(n = 131)AKI (n = 159)Non-AKI(n = 1484) Basic personal information Age, year (mean, sd)73.54 ± 14.0275.50 ± 13.9775.11 ± 12.580.70878.21 ± 11.5872.83 ± 14.28 0.000 0.357Gender(Male/Female), n(%)1056(58.0)/764(42.0)32(69.6)/14(30.4)81(61.8)/50(38.2)0.348108(67.9)/51(32.1)835(56.3)/649(43.7) 0.006 0.833Length of Hospital Stay, days, Median (IQR)10(7–13)12(8–16)10(7–13)0.03512(8–18)9(7–13) 0.000 0.885Systolic blood pressure, mmhg, Median (IQR)134(120–149)134(118–150)136(121–154)0.341129(110–148)134(121–149) 0.008 0.329Diastolic pressure, mmhg, Median (IQR)76(68–84)74(65–83)77(69–83)0.29373(65–82)77(69–85) 0.007 0.933Underlying disease, n(%)Diabetes477(26.2)22(47.8)63(48.1)0.97552(32.7)340(22.9) 0.006 0.060Hypertension900(49.5)28(60.9)92(70.2)0.24398(61.6)682(46.0) 0.000 0.925Oxygen intaken, n(%)Noninvasive oxygen therapy163(9.0)9(19.6)18(13.7)0.34534(21.4)102(6.9) 0.000 0.790Invasive mechanical ventilation116(6.4)9(19.6)6(4.6) 0.002 54(34.0)47(3.2) 0.000 0.062Treatment results, n(%)Improvement1630(89.5)30(65.2)116(88.6) 0.000 81(50.9)1403(86.2) 0.000 0.087Death190(10.5)16(34.8)15(11.5) 0.000 78(49.1)81(5.5) 0.000 0.087 Laboratory data WBC, x109/L, Median (IQR)7.00(5.20–9.60)7.35(5.73–11.10)6.85(5.10–9.15)0.2009.10(6.20–12.70)6.90(5.10–9.28) 0.000 0.075Lymphocyte, x109/L, Median (IQR)0.90(0.60–1.40)0.60(0.40–0.90)0.90(0.58–1.30) 0.000 0.60(0.40-1.00)1.00(0.70–1.50) 0.000 0.436CRP, mg/dl, Median (IQR)15.3(4.1–53.3)32.4(17.7–68.3)22.8(6.5–63.2)0.110100.8(35.3-158.5)12.0(3.4–41.6) 0.000 0.000 K, mmol/L, Median (IQR)4.04(3.71–4.41)4.55(3.98–5.08)4.33(3.92–4.75)0.1954.14(3.79–4.57)3.99(3.68–4.35) 0.001 0.015 NA, mmol/L, Median (IQR)139.3(136.6-141.6)139.8(136.5-144.3)138.4(135.8-141.5) 0.040 139.6(136.1-144.1)139.3(136.8-141.5)0.2380.601CL, mmol/L, Median (IQR)104.1(100.9-107.1)105.4(101.9-111.1)105.5(101.7-108.7)0.367104.4(101.4-109.1)103.9(100.8-106.7) 0.016 0.259Cr, mmol/L, Median (IQR)75(60–101)312(174–574)148(117–234) 0.000 132(100–186)69(57–86) 0.000 0.000 UREA, mmol/L, Median (IQR)6.28(4.64–9.31)24.04(16.90-34.02)11.14(7.90-16.86) 0.000 13.84(9.77–20.37)5.71(4.33–7.70) 0.000 0.000 TP, g/L, Median (IQR)64.4(59.4–69.0)59.8(52.8–68.0)61.2(56.3–67.9)0.44862.9(57.4–68.3)64.8(60.1–69.1) 0.001 0.177ALB, g/L, Median (IQR)34.5(31.2–37.9)30.1(27.2–34.0)33.6(29.5–36.4) 0.003 31.6(27.5–34.0)35.2(31.9–38.3) 0.000 0.334ALT, U/L, Median (IQR)20(14–32)19(13–31)21(14–30)0.95622(13–39)20(14–32)0.0940.516AST, U/L, Median (IQR)30(22–42)37(27–59)29(22–39) 0.002 40(31–68)28(21–41) 0.000 0.448ALP, U/L, Median (IQR)73(60–91)77(58–104)76(59–94)0.63474(60–97)72(60–89)0.2620.711GGT, U/L, Median (IQR)30(20–54)33(19–62)32(21–64)0.83633(21–53)30(19–52)0.3310.830D-Dimer, ng/ml, Median (IQR)0.97(0.52–1.79)1.83(1.12–2.20)0.98(0.64–1.63) 0.000 1.99(1.05–2.81)0.88(0.47–1.58) 0.000 0.324PT, sec, Median (IQR)13.4(12.9–14.1)14.1(13.4–15.3)13.4(12.9–14.3) 0.001 14.1(13.3–15.2)13.3(12.8–14.0) 0.000 0.676APTT, sec, Median (IQR)37.4(34.1–41.4)41.0(36.6–48.8)38.4(35.2–41.8) 0.006 40.2(35.9–45.2)37.0(33.8–40.8) 0.000 0.302Glomerular filtration rate, ml/min/1.73m2,Median (IQR)81(57–93)14(7–29)34(21–47) 0.000 40(25–59)85(71–96) 0.000 0.000 CKD staging, ml/min/1.73 m2,n(%)≥ 90582(32.0)0(0.0)3(2.3)0.2996(3.8)573(38.7) 0.000 0.18160–89748(41.2)1(2.2)15(11.5)0.05831(19.5)701(47.3) 0.000 0.004 45–59192(10.6)3(6.5)17(13.1)0.22928(17.6)144(9.7) 0.002 0.06530–44142(7.8)6(13.0)42(32.3) 0.012 40(25.2)54(3.6) 0.000 0.08315–2998(5.4)12(26.1)35(26.9)0.91243(27.0)8(0.5) 0.000 0.897<1555(3.0)24(52.2)19(14.5) 0.000 11(6.9)2(0.1) 0.000 0.000 Note: P-value1 compares the CKD-AKI group with the CKD-Non AKI group, P-value2 compares the Non CKD-AKI group with the Non CKD-Non AKI group, and P-value3 compares the CKD-AKI group with the Non CKD-AKI group Clinical baseline characteristics Note: P-value1 compares the CKD-AKI group with the CKD-Non AKI group, P-value2 compares the Non CKD-AKI group with the Non CKD-Non AKI group, and P-value3 compares the CKD-AKI group with the Non CKD-AKI group The Non CKD-AKI group and the Non CKD-Non AKI group showed significant differences in age, gender, length of hospital stay, underlying diseases, oxygen therapy status, and treatment efficacy. Regarding laboratory data, all indicators except Na, ALP, and GGT demonstrated significant differences between the two groups. The CKD-AKI group and Non CKD-AKI group showed no significant differences in age, gender, length of hospital stay, underlying diseases, oxygen therapy status, or treatment efficacy. However, significant differences were observed between the two groups in CRP, K, BUN, CREA, eGFR, and other indicators (Table 1). Multivariate logistic regression analysis demonstrated that CKD stage (stages 3b–5 vs. stages 1–3a; odds ratio [OR] 12.579, 95% confidence interval [95% CI] 1.618–97.801, P = 0.016) was an independent risk factor for AKI in patients with preexisting CKD, while white blood cell (WBC) count was identified as an independent risk factor for AKI in Non CKD patients (Table 2). Table 2Multivariate logistic regression analysis of AKI incidence in CKD and Non CKD patientsVariablesCKDNon CKDUnivariate AnalysisMultivariate AnalysisUnivariate AnalysisMultivariate AnalysisOR(95%CI)P valueOR(95%CI)P valueOR(95%CI)P valueOR(95%CI)P value Basic personal information Age0.998(0.972–1.024)0.8591.032(1.018–1.046)0.0000.953(0.932–0.974)0.000Gender(Female vs. Male)1.383(0.672–2.844)0.3790.608(0.429–0.861)0.0050.478(0.290–0.789)0.004 Underlying disease Diabetes (YES vs. NO)0.975(0.497–1.911)0.9411.635(1.149–2.327)0.0061.309(0.782–2.192)0.305Hypertension (YES vs. NO)0.667(0.331–1.344)0.2511.889(1.351–2.643)0.0001.147(0.704–1.870)0.581 CKD stages CKD(1-3a stage)1(Comparison)1(Comparison)CKD(3b-5 stage)16.579(2.201-124.873)0.00612.579(1.618–97.801))0.016 Laboratory data WBC1.110(1.076–1.145)0.0001.106(1.057–1.158)0.000Glomerular filtration rate0.925(0.916–0.934)0.0000.921(0.909–0.932)0.000Lymphocyte0.318(0.144–0.705)0.0010.511(0.223–1.168)0.1120.256(0.173–0.379)0.0000.508(0.322–0.803)0.004ALB0.914(0.857–0.975)0.0060.962(0.898–1.030)0.2680.857(0.828–0.887)0.0000.931(0.885–0.978)0.005APTT1.083(1.033–1.136)0.0011.050(0.996–1.107)0.0721.071(1.048–1.094)0.0001.006(0.976–1.038)0.686PT1.224(1.024–1.464)0.0261.099(0.878–1.376)0.4091.175(1.094–1.262)0.0001.036(0.953–1.126)0.410D-Dimer1.087(0.987–1.197)0.0891.097(1.057–1.139)0.0001.021(0.958–1.087)0.525 Multivariate logistic regression analysis of AKI incidence in CKD and Non CKD patients Clinical characteristics of 205AKI cases Among the 205 patients diagnosed with AKI, 46 were from the preexisting CKD group and 159 from the Non CKD group. Comparisons were performed between the two groups regarding COVID-19 clinical severity classification, AKI onset timing, AKI duration, and AKI stage. Results indicated a significant difference in AKI duration between the two groups (P < 0.05), with the CKD group demonstrating a longer AKI duration than the Non CKD group. Additionally, a significant difference was observed in the proportion of critically ill patients across clinical severity classifications: 15 patients (32.6%) in the CKD-AKI group were critically ill, whereas 82 patients (51.6%) in the Non CKD-AKI group were critically ill, indicating that the proportion of critically ill patients was significantly higher in the Non CKD-AKI group compared to the CKD-AKI group (Table 3). Table 3Comparison of 205 AKI patients in the CKD-AKI and Non CKD-AKI groupsTotal(n = 205)CKD-AKI(n = 46)NON CKD-AKI(n = 159)P-valueClinical classification of COVID-19 infection-n(%)Critical97(47.3)15(32.6)82(51.6) 0.023 Severe63(30.7)19(41.3)44(27.7)0.078Moderate45(22.0)12(26.1)33(20.7)0.442Course and kidney injury-related time, days, Median (IQR)From onset to discharge18(13–25)19(14–28)18(13–25)0.37From onset to admission5(2–8)5(2–9)5(2–7)0.379From admission to discharge12(8–18)12(9–17)12(8–19)0.882From onset to peak8(5–13)8(6–12)8(4–13)0.978From onset to the appearance of kidney damage6(4–11)11(6–15)6(4–11)0.947Duration from onset to renal injury11(7–17)17(12–24)10(6–16)0.292Duration of kidney damage3(2–8)5(2–9)3(1–8) 0.029 Creatinine peak, mmol/L, Median (IQR)232(158–347)400(270–624)191(147–297) 0.000 AKI stages-n(%) AKI-169(33.7)13(27.7)56(35.4)0.322AKI-282(40.0)23(48.9)59(37.3)0.154AKI-354(26.3)11(23.4)43(27.2)0.603 Comparison of 205 AKI patients in the CKD-AKI and Non CKD-AKI groups Analysis of characteristics of AKI-related fatal cases The 205 AKI patients were stratified into a survivor group (111 cases) and a non-survivor group (94 cases). Comparisons of clinical characteristics, comorbidities, AKI staging, and laboratory data were conducted between the two groups. Results showed that the non-survivor group had significantly higher proportions of intubated patients, severe COVID-19 cases, and elevated D-dimer levels compared to the survivor group (all P < 0.05), while no significant differences were observed for the remaining indicators. Multivariate logistic regression analysis was performed to identify factors influencing mortality risk in AKI patients, revealing that critical COVID-19 (vs. moderate COVID-19; odds ratio [OR] 96.499, 95% confidence interval [95% CI] 18.907–503.172, P < 0.001) was a significant predictor of mortality in this patient population (Table 4). Table 4Analysis of factors influencing mortality in AKI patientsSurvival(n = 111)Deceased(n = 94)Univariate AnalysisMultivariateAnalysisOR(95%CI)P valueOR(95%CI)P value Basic personal information Age, year (mean, sd)76.27 ± 13.2579.18 ± 10.601.020(0.997–1.045)0.090Gender(Male/Female), n(%)73(65.8%)/38(34.2%)67(71.3%)/27(28.7%)1.292(0.713–2.341)0.399Endotracheal intubation13(11.7%)50(53.2%)0.117(0.058–0.237) 0.000 1.141(0.408–3.194)0.802Underlying disease, n(%)1.540(0.868–2.732)0.140Diabetes35(31.5%)39(41.5%)0.863(0.491–1.517)0.609Hypertension70(65.8%)56(59.6%)0.554(0.280–1.095)0.089Chronic Kidney Disease30(27.0%)16(17.0%) Clinical classification of COVID-19 infection-n(%) Moderate2(2.1%)45(22.0%)1(Comparison)1(Comparison)Severe52(46.8%)11(11.7%)4.548(0.956–21.640)0.0574.427(0.924–21.214)0.063Critical16(14.4%)81(86.2%)108.844(23.906-495.561)0.00096.499(18.507-503.172) 0.000 AKI stages-n(%) AKI-143(38.7%)30(31.9)1(Comparison)AKI-247(42.3%)39(41.5%)1.189(0.633–2.234)0.590AKI-321(18.9%)25(26.6%)1.706(0.811–3.592)0.159 Laboratory data UREA, mmol/L, Median (IQR)16.67(10.56–23.74)15.42(11.14–23.69)D-Dimer, ng/ml, Median (IQR)1.53(0.89–2.42)2.14(1.32–3.78)1.094(1.006–1.191) 0.037 1.011(0.907–1.127)0.844PT, sec, Median (IQR)14.1(13.3–15.3)14.0(13.2–15.1)APTT, sec, Median (IQR)40.8(36.8–46.3)41.1(35.45–44.9) Analysis of factors influencing mortality in AKI patients No statistically significant difference was found in the time from COVID-19 symptom onset to hospital admission between the CKD-AKI and Non CKD-AKI groups, regardless of survival status (detailed data shown in Fig. 2A). Regarding the time from symptom onset to discharge, no difference was observed between survivors and non-survivors in the CKD-AKI group, whereas a significant difference existed between survivors and non-survivors in the Non CKD-AKI group (P < 0.001); furthermore, among survivors, a statistically significant difference in this time interval was noted between the CKD-AKI and Non CKD-AKI groups (P < 0.05) (Fig. 2B). The length of hospital stay (from admission to discharge) showed no statistically significant difference between survivors and non-survivors in the CKD-AKI group, but a significant difference was observed in the Non CKD-AKI group (P < 0.01), with survivors having a relatively longer hospitalization duration (Fig. 2C). Analysis of key time points in AKI-related deaths A: Time from onset to admission; B: Time from onset to discharge; C: Time from admission to discharge; D: Time from onset to onset of acute kidney injury; E: Time from onset to peak creatinine level; F: Duration of acute kidney injury. Note: *: P < 0.05; **: P < 0.01; ***: P < 0.001 In the CKD-AKI group, the onset of AKI occurred earlier in survivors than in non-survivors, with a statistically significant difference (P < 0.05) (Fig. 2D). Additionally, in both the CKD-AKI and Non CKD-AKI groups, the time from AKI onset to peak serum creatinine was longer in non-survivors than in survivors, with statistically significant differences observed in both groups (Fig. 2E). Among survivors, the duration of AKI was longer in the CKD-AKI group (mean 5.9 days) than in the Non CKD-AKI group (mean 3.8 days), representing a statistically significant difference (P < 0.05). Furthermore, within the CKD-AKI group, no significant difference in AKI duration was observed between non-survivors and survivors; in contrast, in the Non CKD-AKI group, non-survivors exhibited an average AKI duration prolonged by approximately 3 days compared to survivors, with a statistically significant difference (P < 0.01) (Fig. 2F). Analysis of AKI incidence in cases at different stages of CKD A total of 177 patients with preexisting CKD were enrolled, with renal function stages distributed as follows (Fig. 3): Stage 1: 3 cases (1.7%); Stage 2: 16 cases (9.0%); Stage 3a: 20 cases (11.3%); Stage 3b: 48 cases (27.1%); Stage 4: 47 cases (26.6%); Stage 5: 43 cases (24.3%). The study results showed that the incidence of acute kidney injury (AKI) exhibited a gradient increase with worsening renal function, rising from 12.5% in stage 3b to 55.8% in stage 5. The distribution characteristics of AKI across different CKD stages were as follows: 13 patients (28.3%) developed Stage 1 AKI, primarily occurring in Stage 3b ~ 5 patients; 22 patients (47.8%) developed Stage 2 AKI, distributed across Stage 3a ~ 5 patients; AKI stage 3 cases numbered 11 (23.9%), most concentrated in stage 5 patients (n = 7). Notably, patients with stage 2 or 3a CKD combined with AKI stage 3 exhibited extremely high risk, while stage 5 CKD combined with AKI stage 3 though the largest cohort (n = 7) showed an unexpectedly high survival rate (85.7%). Analysis of the entire cohort of 177 CKD patients revealed an overall mortality rate of 17.5%. Deaths were predominantly concentrated among patients with CKD stages 3b to 5 (74.2%, 23/31). The mortality rate among AKI patients (34.8%, 16/46), particularly those with CKD stages 3b to 5 (33.3%, 14/42), was significantly higher than that of Non AKI patients (11.5%, 15/131). This data underscores the substantial impact of AKI on prognosis in CKD patients. Analysis of AKI and mortality in different stages of CKD Analysis of organ failure in fatal cases between the CKD-AKI group and the Non CKD-AKI group A detailed analysis of organ failure preceding death was performed for the 94 fatal AKI cases. Among the 16 fatal cases in the CKD-AKI group, 8 (50%) died of renal failure complicated by respiratory, cardiac, and/or circulatory failure (Fig. 4A). Comparison of Organ Failure in Fatal Cases Between CKD and Non-CKD Groups A: Organ failure in 16 fatal cases in the CKD group B: Organ failure in 78 fatal cases in the NON-CKD group Among the 78 fatal cases in the Non CKD-AKI group, 12 deaths (15% of fatal cases) resulted from renal failure complicated by respiratory and/or cardiac failure; additionally, 50 deaths were attributed to isolated respiratory failure, 8 to respiratory failure complicated by cardiac failure, and 2 to isolated cardiac failure (Fig. 4B). Temporal sequence analysis of organ failures in 20 fatal cases with Rena failure Among the 94 fatal cases in the CKD-AKI and Non CKD-AKI groups, renal failure was present at the time of death in 20 cases. To clarify the relationship between death and renal injury, the temporal sequence of organ failure at the time of death was analyzed for these 20 fatal cases with renal failure (Fig. 5). Timeline analysis of organ failure in 20 cases of death due to renal failure Among the fatal cases in the CKD-AKI group, 8 patients developed renal failure: 1 patient ultimately died of isolated renal failure, 1 experienced renal failure prior to respiratory failure, and the remaining 6 developed renal failure concurrently with respiratory failure. In the Non CKD-AKI group, renal failure occurred in 12 fatal cases: 3 patients developed concurrent renal and respiratory failure, while the remaining 9 developed respiratory failure preceding renal failure. Discussion This study systematically investigated differences in the incidence, clinical progression, and mortality outcomes of AKI between hospitalized COVID-19 patients with and without preexisting CKD among 1,820 enrolled cases, while also conducting the first in-depth analysis of the temporal sequence of renal failure in fatal events. We observed that preexisting CKD significantly elevated the risk of AKI, with this risk increasing progressively as renal function deteriorated; CKD patients also exhibited higher mortality rates, longer AKI duration following onset, and a greater propensity to die due to renal failure. This study found that the overall incidence of AKI among COVID-19 patients was 11.29%, consistent with the global incidence range of 5%–56% reported by Ooi et al. [11]. Notably, the incidence of AKI in CKD patients (26.0%) was significantly higher than in Non CKD patients (9.7%), which closely aligns with the 26.7% AKI incidence rate reported in CKD patients by Jewell PD et al. [12]. This confirms that CKD is a significant risk factor for COVID-19 associated AKI. Multiple studies have established that advanced age, male gender, and comorbidities such as diabetes and hypertension are risk factors for AKI onset [13]. and the present study reaffirms these findings. Furthermore, no significant differences were observed in the distribution of age, gender, diabetes mellitus, hypertension, or other comorbidities between AKI patients in the CKD group and those in the Non CKD group. This contrasts with the findings of Aroca-Martínez G et al. [14], potentially attributed to the more complex mechanisms by which these factors influence outcomes across different CKD statuses, and such variations may be modulated by disease severity, clinical medication use, and patient lifestyle-related factors. More critically, our analysis of AKI risk factors in the CKD cohort identified that advanced CKD stages (3b–5) constitute a significant independent risk factor for AKI following SARS-CoV-2 infection, with a substantially higher risk compared to early-stage CKD (1–3a). This underscores the necessity of closer monitoring for AKI in patients with advanced CKD during COVID-19 hospitalization. Notably, the risk of AKI increased incrementally with each progressive CKD stage and declining estimated glomerular filtration rate (eGFR), reaching 55.8% in stage 5 patients. Furthermore, deaths subsequent to AKI primarily occurred in patients with CKD stages 3b–5, suggesting that clinical management should stratify CKD patients early after COVID-19 hospitalization to detect subclinical AKI. Of note, patients with CKD stage 5 complicated by AKI stage 3 had a relatively high survival rate of 85.7%, however, since this study did not collect data on the administration of renal replacement therapy (RRT), we cannot establish a causal link between this survival rate and the therapeutic effect of RRT. Regarding the proposal put forward by Gameino J et al. [15] to relax the initiation criteria for RRT in non-dialysis-dependent CKD patients, the validity of this suggestion requires further verification through prospective studies. Analysis of mortality rates revealed that the mortality rate in the CKD-AKI group (34.8%) was significantly higher than that in the CKD-Non AKI group (11.5%), and the mortality rate in the Non CKD-AKI group (49.1%) was also substantially higher than that in the Non CKD-Non AKI group (5.5%).This is consistent with findings from Chan et al. [16], Hirsch et al. [17], and Wan YI et al. [18], which collectively indicate that AKI increases the mortality risk in COVID-19 patients. The underlying mechanisms likely involve shared pathogenic pathways such as inflammatory storm, microthrombosis, immunosuppression, and kidney-lung crosstalk [19, 20]. AKI-induced volume overload and immune dysregulation exacerbate lung injury [21], while lung injury treatment and associated complications (e.g., mechanical ventilation, hypoxia, and hypercapnia) further aggravate renal ischemia, thereby worsening AKI severity [22, 23]. However, the clinical outcomes of COVID-19 patients with AKI are also influenced by the severity of COVID-19 infection, Our multivariate analysis of mortality-related factors in AKI patients revealed that COVID-19 severity significantly impacts patient prognosis, with the risk of death increasing markedly following AKI onset, particularly among critically ill patients. Additionally, we observed that the time from AKI onset to peak serum creatinine was significantly longer in non-survivors than in survivors. In the Non CKD-AKI group, AKI duration was markedly prolonged in non-survivors compared to survivors; in the CKD-AKI group, although the mean AKI duration was longer in non-survivors than in survivors, this difference did not reach statistical significance. Further individual case analysis revealed that some patients received renal replacement therapy (RRT) after AKI onset, which shortened the duration of severe AKI and thus confounded the statistical results. This finding carries significant clinical implications, suggesting that progressive renal injury is not limited to an initial acute insult but represents a dynamic process throughout the disease course. This temporal discrepancy reflects the ongoing progressive nature of renal damage, potentially associated with pathophysiological mechanisms such as persistent inflammatory storms, microcirculatory dysfunction, or direct viral invasion [24]. It highlights the limitations of single-time-point renal function assessment and underscores the need for dynamic, continuous renal function monitoring strategies to more accurately evaluate disease progression and prognosis. In the CKD-AKI group, AKI onset occurred significantly earlier in survivors than in non-survivors (P < 0.05), indicating that early identification and timely intervention for AKI are particularly crucial in patients with concurrent CKD, potentially providing a critical therapeutic window. In the Non CKD-AKI group, both the time from COVID-19 symptom onset to discharge and the length of hospital stay (from admission to discharge) were significantly longer in survivors than in non-survivors (P < 0.001 and P < 0.01, respectively). This suggests that extended hospitalization may enable more comprehensive interventions, potentially improving outcomes in this patient subset. This phenomenon may be related to Non CKD-AKI patients typically having better renal reserve and responding more favorably to treatment; in contrast, no such difference was observed in the CKD-AKI group, implying that underlying CKD may attenuate the moderating effect of treatment duration on outcomes. Thus, clinical management for these patients should prioritize treatment quality over mere prolongation of treatment duration. A time-series analysis of 20 fatal AKI cases with concurrent renal failure revealed that in the CKD-AKI group, renal failure could occur simultaneously with or even slightly precede respiratory failure, whereas in the Non CKD-AKI group, respiratory failure typically preceded renal failure. This may be attributed to poor renal perfusion reserve in CKD patients, where direct viral attack and inflammatory mediators can rapidly trigger renal failure. Therefore, CKD-AKI patients should undergo intensive renal function monitoring with early interventions, including adequate hemodynamic support and avoidance of nephrotoxic medications to improve prognosis [25]. For Non CKD-AKI patients, prioritizing prevention and control of respiratory failure-related risks is essential for enhancing outcomes. This retrospective cohort study has certain limitations, including the inability to comprehensively collect data on urine output and urine albumin-to-creatinine ratio, which may introduce bias into the findings. Future studies should adopt prospective designs to further validate these conclusions. In summary, CKD significantly amplifies the risk of COVID-19-associated AKI and mortality, with renal function stage, AKI severity, and AKI duration determining prognosis. Implementing stratified monitoring, early intervention, and multidisciplinary collaboration tailored to different patient populations holds promise for improving outcomes in this high-risk cohort. Acknowledgements We thank all participants for their cooperation in this study. Author contributions Xianhong Ding: Definition, Methodology, Software, Formal Analysis, Investigation, Data Organization, Draft Writing, Project Management; Tong Sun: Definition, Methodology, Resources, Writing-Draft, Data Management, Visualization; Mengyuan Chen: Methodology, Data Management, Visualization; Tianbin Tang: Data Management, Visualization; Guangjun Zhu: Data Management, Resources; Ying Zhang: Data Curation, Resources; Shenyi Ye: Methodology, Data Management; Yang Lu: Methodology, Data Management; Bo Shen: Definition, Methodology, Research, Conceptualization, Oversight, Project Management. Funding No funding was received. Data availability The data and materials supporting the results or analyses presented in this paper are available upon reasonable request. Declarations Ethics approval and consent to participate This study received approval from the Ethics Committee of Taizhou Hospital, Zhejiang Province (k20230116) and adheres to the ethical principles outlined in the Declaration of Helsinki. Considering the retrospective design of the study, the Ethics Committee of Taizhou Hospital, Zhejiang Province, granted an exemption from obtaining informed consent. All data were anonymized and maintained strict confidentiality. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xianhong Ding and Tong Sun contributed equally to this work. References Associated Data Data Availability Statement The data and materials supporting the results or analyses presented in this paper are available upon reasonable request.